How MaxCyte Has Evolved to Become Leading Technology Provider for Cell Engineering and Leveraged Its Flow Electroporation® Technology and Know-How to Launch Its Own Robust CAR Pipeline MaxCyte, located in Gaithersburg, Maryland, is a unique biotech company that is a key anchor of the robust and growing Maryland cell and gene therapy industry. Founded in 1999, […]
CAMBRIDGE, Mass., and GAITHERSBURG, Md., – October 7, 2019:– Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and MaxCyte, Inc., the global cell-based therapies and life sciences company, today announced a new clinical and commercial license agreement. Editas Medicine will use MaxCyte’s Flow Electroporation® technology and ExPERT™ instruments for the advancement of engineered cell […]
– No dose-limiting toxicities or safety concerns observed in first cohort of treated patients– Feasibility of streamlined, faster CAR therapy manufacturing process confirmed– Dosing initiated in second cohort of patients Gaithersburg, Maryland – May 8, 2019: MaxCyte, the global clinical-stage cell-based therapies and life sciences company, announced today that it […]
– CARMA drug candidates can be manufactured via streamlined, single-day process, providing a much needed faster turnaround of autologous cell therapy to patients– CARMA cell therapies are engineered with the intention of reducing potential adverse events that have been evident with other CAR technologies and to allow for multiple dosing, an important feature for potential […]
